Development of neuronal and glial cells and their maintenance are under control of neurotrophic factors (NTFs).
certain species of neural cells. Thus, the purpose of this review is to summarize the present understanding of the role of NTFs in normal and ischemic brain and the therapeutic potential of NTF protein itself or gene therapy, and then to summarize the role of NTFs in stem cell differentiation and a possible thera peutic potential with the neural stem cells against ischemic brain injury. Key Words : Cerebral ischemia-Neurotrophic factor-Gene therapy-Neural stem cell-Transplantation. ever, brain cells have long been believed not to differ entiate again once they have matured with normal devel opment. Recent advancements in molecular cell biology have discovered the presence of neural stem cells even in mature adult mammalian brain. It is now expected that neural stem cells have the potential to compensate and recover neural functions that were lost because of isch emic stroke. These stem cells are also under the control of NTFs to differentiate into a certain species of neural cells. Therefore, understanding the role of NTFs as a possible therapeutic potential and in a differentiation of neural stem cell may be essential to propel future devel opment of the treatment for human stroke patients.
The purpose of this review is to summarize the present understanding of the role of NTFs in normal develop ment and ischemic brain, and the therapeutic potential of NTF protein itself or of gene therapy, and then to sum marize the role of NTFs in stem cell differentiation and as a possible therapeutic potential with neural stem cells.
DEVELOPMENTAL AND PHYSIOLOGIC ROLE OF NEUROTROPHIC FACTORS
A number of protein peptides affect target cells in different ways (Fig. I) . Endocrine hormones have a re mote effect on their target cells through systemic circu lation. In contrast, NTFs affect target cells by paracrine, autocrine, or juxtacrine (Fig. 1 ). This suggests a local role for NTFs in cell proliferation, migration, differen tiation, and production of extracellular matrix in the ner vous system. A study on epidermal growth factor (EGF) suggests that paracrine stimulation transiently activates intracellular signals and has a direct effect on prolifera tion, whereas juxtacrine stimulation continuously acti vates intracellular signals and has a greater effect on differentiation and survival (Higashiyama et aI., 1995) . Neurotrophic factors usually promote cell proliferation, but sometimes inhibit such a proliferation under certain circumstances or for a certain cell species. For example, fibroblast growth factor (FGF) inhibits proliferation of chondroblast, and a constant activation of FGF effect with FGF receptor mutation causes achondroplasia (Deng et aI., 1996; Naski et aI., 1996) . Transforming growth factor (TGF)-� was originally found to promote transformation and growth of fibroblast. However, a recent study suggests that TGF-� usually inhibits cell growth for most epidermal cells (Royuela et aI., 1998) . Neurotrophic factors are usually classified into 3 or 4 subclasses based on their receptors (Table I; Fig. 2 ). Neurotrophic factors that work with tyrosine kinase re ceptors are a major group consisting of EGF, FGF, he patocyte growth factor (HGF), insulin-like growth factor (IGF-l ), neurotrophins (nerve growth factor [NGF], brain-derived neurotrophic factor [B DNF], neurotrophin 3 [NT3], neurotrophin 4/5 [NT4/5]), platelet-derived growth factor (PDGF), vascular endothelial growth fac tor (VEGF), and so on. Once these proteins bind the receptors as monomer (FGF) or dimer (neurotrophins), the receptors form dimer and the intracellular tyrosine kinase domains are activated, those then transphosphory late intracellular signal proteins that possess SH2 (Src homology 2), SH3, or PH (pleckstrin homology) domain (Table I ; Fig. 2A ). Glial cell line-derived neurotrophic factor (GDNF) and colleague proteins-such as neur turin, artemin, and persephin-bind receptor complex of GFRa and c-ret as a monomer, then the intracellular tyrosine kinase domain is activated ( Fig. 2B ). Cyto kines-such as ciliary neurotrophic factor (CNTF), leu kemia inhibitory factor (LIF), and interleukin-2 (IL-2) bind dimeric or trimeric receptors and activate intracel lular tyrosine kinase proteins such as JAK (Table 1; Fig.  2C ). The TGF-� super family consists of the activin family (activin-�A and -�B), bone morphogenetic pro tein (BMP) family (BMP2-8, OPI-2, GDF5-7, and so on), and TGF-� family (TGF-� 1-3). Transforming growth factor-� ligands bind to types 1 and 2 receptors, and the receptors form tetrameric fu nctional complex. Then type 2 receptors phosphorylate serine-threonine ki nase domain of type I receptors so that the type 1 receptors EGF, epidermal growth factor; TGF, transforming growth factor; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; NGF, nerve growth factor; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor: CNTF, ciliary neurotrophic factor; LIF, leukemia inhibitory factor; BMP, bone morphogenetic protein. activate subsequent signal systems such as Smad (Table  I ; Fig. 2D ) .
Examples of the roles of NTFs in normal cellular de velopment and differentiation are shown in Fig. 3 . Many different classes of neurons. glial cells, and other cell types develop from the multi potent neural crest cells (Fig. 3A) . Specific growth factors control the fate of certain neural crest cells. Bone morphogenetic proteins (BMPs) 2 and 4 promote the differentiation of sympa thetic neurons, glial growth factor (GGF) represses neu rogenesis and promotes Schwann cell differentiation, and TGF-(3 promotes smooth muscle cell differentiation (Fig.  3A ). In optic nerve ( Fig. 3B ), PDGF secreted by astro cytes maintains the proliferation of oligodendrocyte pro genitor cells. Postnatally, these progenitor cells begin to differentiate into oligodendrocytes or astrocytes with or without CNTF secreted by astrocytes ( Fig. 3B ; Lillien and Raff, 1990) . In sympathoadrenal lineage of the neu ral crest ( Fig. 3C ), sympathoadrenal precursor cells dif ferentiate into adrenal chromaffin cells, noradrenergic and cholinergic sympathetic neurons with glucocorti coids, FGF/NGF, or LIF/CNTF, respectively. Thus, NTFs are actively involved in many steps of normal cell development and differentiation (Fig. 3; Jessell and Sanes, 2000) .
Neurotrophic factors are also involved in normal maintenance and survival of neuronal cells after differ entiation. Constant secretion of NTFs keep cell survival signals activated and death signals inactive ( Fig. 4 ). For example, the presence of nerve growth factor maintains cell survival by activating cell survival Bcl-2 and inhib iting death signals such as Apaf-1 and caspases (Jessell and Sanes, 2000) . However, once NTFs are deprived for some reason, such as ischemia, the balance between sur vival and death signals is tapped in favor of death signals that finally result in neuronal cell death. Many other stimuli-such as reactive oxygen species (ROS), FAS ligand, and tumor necrosis factor (TNF)-activate a dis tinct biochemical pathway that triggers a fam ily of caspases and leads to cell death.
INDUCTION OF NEUROTROPHIC FACTORS AFTER ISCHEMIA
Under pathologic conditions such as ischemia and kinate-induced seizures, NTFs-such as BDNF, bFGF, GDNF, NGF, and TGF-(31 -are induced in bf'i\\\'. cells (Kato et a!., 1992; Logan et a!., 1992; Comelli et a!., 1993; Humpel et a!., 1994; Lee et aI., 1994) . However, each NTF species shows a different temporal and cellular distribution. Glial cell line-deri ved neurotrophic factor was originally associated with survival and neurite out growth of dopaminergic and motor neurons as well as peripheral sensory and sympathetic neurons (Henderson , and no glial cell was stained in the brain sections . Ciliary neurotrophic factor abundantly expressed in astroglial and Schwann cells was identified as a neuro trophic molecule for parasympathetic ciliary ganglion neurons, but also affected the survival of other neuronal cells (Barbin et a!., 1984; Arakawa et aI. , 1990 , Ip et aI., 1991 . Ciliary neurotrophic factor levels were signifi cantly higher in the frontal, parieto-temporal, and occipi tal lobes at 2 days after 120 minutes of transient MCAO (Hu et aI., 1997) . With subsequent immunohistochemical analysis, astrocytes were predominantly stained in the marginal region of the infarct from I day to 7 days of reperfusion after 90 minutes of transient MeAO (Fig. 6 ).
Vascular endothelial growth factor, also known as vascular permeability factor, is mitogenic for endothe lial cells. By alternative splicing four different isoforms exist in vivo: VEGF206, VEGF 189, VEGF I6S, and VEGF121; VEGF 16S and VEGFI21 act as diffusible factors. A recent report (Hayashi et aI., 1997) showed that immunoreactive VEGF was normally present in the ependymal cells, but was not in neurons ( Fig. 7a ), glial cells, vascular endothelial cells, or pial cells ( Fig.  7e ) in control brains. However, neurons of the ischemic cerebral cortex stained positively for VEGF from I hour ( Fig. 7b ) to I day ( Fig. 7d ) of reperfusion after 90 min utes of transient MCAO with a peak at 3 hours (Fig 7c) . Pial cells of the MCA area became positive for VEGF from I hour with a peak at 3 hours ( Fig. 7f ), which was sustained until 3 to 7 days of reperfusion ( Fig. 7g , arrowhead). 
Apoptotic Pathways of Cell Death

9
.-
Although GDNF was originally isolated from cultured glial cells, the gene was expressed only in neurons in the current study ( Fig. 5 ). Because the induction of CNTF was predominantly observed in the astroglia of the mar ginal region (Fig. 6 ), injured neurons may stimulate the synthesis of CNTF in astroglia, which may in turn sup port survival and regeneration of neurons in the injured regions. Because the VEGF gene was al so induced in other brain cells under hypoxic conditions or during con tinuous MCAO (Fischer et aI., 1995; lj ichi et aI., 1995; Nomura et aI., 1995; Kovacs et aI., 1996) , sensitivity for inducing the VEGF gene may be different in each neural cell type under conditions of hypoxia-ischemia or con tinuous ischemia-reperfusion. Neovascularization usu al ly begins at 2 to 5 days after the ischemic insult and continues for months (Krupinski et aI., 1994) . Therefore, the sustained expression of the VEGF gene in the pia mater after ischemia ( Fig. 7e to 7h 
h new vessel formation in the affected area. However, the rapid and transient induction of VEGF in neurons ( Fig.  7a to 7d) may be related to the protection of the vascular system against ischemic damage. Thus, NTFs are induced in different neural cell types (neuronal, astroglial, and pial) with different temporal profiles, suggesting a different role of each NTF for each neural cell species at a particular stage after ischemia (Table 2) .
PROTECTIVE EFFECTS AND THE MECHANISM OF ACTION OF NEUROTROPHIC FACTORS IN ISCHEMIC BRAIN INJURY
Neurotrophic factors are essential for the survival and differentiation of normally developing neurons, but they also play important roles in the protection and recovery FIG. 6. Ciliary neurotrophic factor (CNTF) immunohistochemis try after 90 minutes of transient middle cerebral artery occlusion at 3 days of reperfusion. Infarction is obvious in the right caudate with CNTF staining in the marginal region (A). Ciliary neuro trophic factor staining is more evident with moderate magnifica tion (8). High magnification shows a predominant staining in as trocytes (C).
of mature neurons under pathologic conditions (Lin et aI.. 1993) . Ga1ectin-l regulates initial axonal growth in peripheral nerves after axotomy (Horie et aI., 1999) . Pro tective effects of GDNF in various injuries for central and peripheral nervous tissue have been reported (Schaar et aI., 1993; Krieglstein et aI. , 1995) . Ciliary neuro trophic factor infusion prevented the learning disability In contrast to control (a), note gradual increase of staining from 1 hour (b, arrowheads) to 3 hours (c) in many neurons, which almost disappeared at 1 day with one exception (d, arrow head). In contrast, note prolonged staining in the pia mater from 3 hours (f, arrowhead) to 3 days (g, arrowhead). Negative stain ing in control pia mater (e). The expression of immunoreactive VEGF was restricted to the MCA territory (h, from black arrow head to bottom of panel). Pia mater in the ipsilateral anterior cerebral artery territory (h, above black arrowhead) was not VEGF positive. Referred from Hayashi et al. (1997) . and neuronal loss induced by ischemia in gerbils (Wen et a!., 1995) . To examine possible direct protective effect of NTF proteins against ischemic brain damage, topical admin istration of NTFs such as GDNF, NT-3, VEGF, IGF-l, and BDNF onto the ischemic brain surface have recently been tried in continuous and transient focal cerebral isch emia models. Kitagawa et a!. (l998b) reported that topi cal application of GDNF greatly reduced the infarct size (48%) and brain edema (30%) at 24 hours of continuous MCAO in rats. The reduction of the infarct size was not related to a change of cerebral blood flow (CBF), but was accompanied by marked reduction in TUNEL and caspase positive cells in the affected area ( Fig. 8) . Thus, GDNF showed a direct protective effect against ischemic brain damage, but not by improving CBF (Fig. SD) . In duction of TUNEL was located primarily in the ischemic core, and induction of caspases I to 3 was mainly in the penumbra, suggesting that the main mechanism of isch emic neuronal cell death is necrosis in the core and ap optosis in the penumbra. Although the infarct size be came smaller with GDNF treatment, the dissociative spa tial distribution among TUNEL and caspases 1 to 3 positive cells was similar to vehicle treatment (Fig. 8E ). These data suggest that treatment with GDNF was pro tective not only by reducing the apoptotic process, but also by reducing the necrotic process. Similar results were obtained with different NTFs and animal models, but ischemic injury was smaller with shorter periods of transient focal ischemia than with con tinuous ischemia. In fact, reduction of brain edema by GDNF was greater with transient MCAO (Abe et al., 1997a) than with continuous MCAO (Kitagawa et al., 1998a) in rats. In transient MCAO models, treatment of ischemic rats with topical application of NT-3, VEGF, and IGF-l ameliorated infarct sizes and was associated with a reduction in the number of TUNEL and caspase positive cells (Hayashi et al., 1998; Zhang et al ., 1999 , Wang et al., 2000 . However, the pharmacologic potency was strongest for GDNF (that is, GDNF > NT-3 > VEGF > IGF-I in this order). Yamashita et al. (1997) delivered BDNF into the territory of MCA through an osmotic mini-pump (I ,..Ll hr) and found a 33% reduction in total infarct volume.
In terms of the protective mechanism of NTFs on isch emic brain injury, exogenously administered excessive amounts of NTFs could partially inhibit activation of the apoptotic signal cascade, including caspases, and could in turn potentiate survival signal pathways (Fig. 4) . How ever, GDNF was also protective in the cases of continu ous ischemia in which the necrotic mechanism was more important than the apoptotic mechanism (Kitagawa et al., 1998b) . Thus, treatment of NTFs may have the potential to be protective against apoptotic and necrotic mecha nisms of cell death. These potent effects of NTFs against ischemic brain injury could have applications for im provement in clinical outcome for human stroke, or even to prolong the therapeutic time window for an alternative effecti ve therapy.
GENE THERAPY FOR THE ISCHEMIC BRAIN USING NEUROTROPHIC FACTOR GENES
Gene delivery systems using virus vectors have been reported in many fields including not only genetic dis-eases but also in some acquired diseases such as cere brovascular diseases and cancer (Heistad and Faraci, 1996; Karpati et al., 1996; Abe et al., 1997b) . Initial experimental gene transfer into the brain was performed with replication-defective herpes simplex virus (HSV) type 1 (Pallela et al., 1989; Fink et al., 1992; Wolfe et al., 1992) . Although HSV vectors can carry a relatively large gene of up to 36 kb, cytopathogenicity such as neuronal death may be a major disadvantage (Breakfield, 1993; Culotta, 1993; Mulligan, 1993) . The advantages and dis advantages of each vector is shown in Table 3 . Retroviral vectors also have the potential to deliver genes into the brain (Price et al., 1987; Walsh and Cepko, 1988) . How ever, the retroviral vectors do not infect nondividing cells such as neurons, and in vivo risks of mutagenesis and tumorinogenesis are also indicated (Mulligan, 1993; Karpati et al., 1996) . Lentivirus can transduce a gene to nondividing cells and has long-term expression, but has the potential to cause insertional mutagenesis (Kafri et al., 1997) . Direct injection of plasmid vector with or without a conjugation of Iiposome also carries genes into the brain and muscle (Ono et al., 1990; Danko et al., 1993) . However, the efficacy of gene expression is low (Ono et al., 1990; Culotta, 1993) .
In an experiment with replication-defective adenoviral vector, the E. coli lacZ gene was already expressed at 8 hours after the inoculation in control brain. The cell num ber of expression and staining gradually increased with a peak at 7 days (Abe et al., 1997b) . In brains exposed to continuous MCAO, the lacZ gene was expressed at 8 hours of ischemia in the cerebral cortex around the in jection needle (Fig. 9a , arrows indicate needle route). With reperfusion after transient 90 minutes of MCAO, no or only a few cells expressed the lacZ gene at 8 hours ( Fig. ge) and 2 days of reperfusion. However, many brain cells expressed the gene at 7 days ( Fig. 9f and 9g ). Cells expressing the lacZ gene were also found in the contra lateral cerebral cortex ( Fig. 9h ). At 21 day of reperfusion, the majority of brain cells were no longer positively stained for the l3-gal blue color. Double staining showed adenovirus vector contaInIng the GDNF gene (Ad GDNF) was prepared, and a possible protective effect of the Ad-GDNF transfer was examined after transient MCAO in the rat. Pretreatment of animals with Ad GDNF 24 hours before a subsequent 90 minutes of tran sient MCAO effectively reduced infarct volume and area ( Fig. II A and II B ) without affecting regional CBF as compared with the vehicle or Ad-LacZ animal groups (Kitagawa et ai., 1999) . With immunohistological analy ses, treatment with Ad-GDNF greatly reduced the num ber of TUNEL, caspase-3, and cytochrome c positive cells (Fig. II C) . No leukocyte infiltration existed in Ad GDNF treated rats. Inhibition of the cytosolic release of cytochrome c by Ad-GDNF (Fig. II Ci) suggests a target of protection in an apoptotic pathway through cyto chrome c and caspase-3 in the penumbra (Fujimura et ai., 1998) .
Many other therapeutic gene studies for cerebral isch emia have been successful in animal models. Adenovi rus-mediated neuronal apoptosis inhibitory protein and an interleukin-l receptor antagonist had protective ef fects against ischemic brain injury (Betz et ai., 1995 ; Xu et ai., 1997) . Herpes simplex virus-mediated HSP72 or Bcl-2 gene transfer improved brain damage in focal isch emia (Linnik et ai., 1995 ; Lawrence et ai., 1997; Yang et ai., 1997 ; Yenari et aI., 1998) . Each vector has some disadvantages such as toxicity or efficacy of gene pression of LacZ gene with continuous ischemia from 8 hours (a) @ =, ' � j @)) ~ to 2 days (b and c) with a few cells positive for glial fibrillary acidic protein and X-Gal (d, filled arrowheads). Note no staining at 8 hours of reperfusion (e) in contrast to explosive staining at 7 days (f and g) with some positive cells in the contralateral hemisphere (h, arrowheads). Referred from Abe et al. (1997b) .
only a small percentage (5% to 10%) of cells that were double positive for glial fibrillary acidic protein and l3-gal ( Fig. 9d, filled arrowheads) . There was only mini mal traumatic injury and leukocyte infiltration (Fig. 9b,  arrow) . Chronological and spatial changes of the staining are illustrated in Fig. 10 . Transient expression of an ad enoviral vector-mediated gene may be advantageous in situations in which it is appropriate for the foreign gene to disappear from the tissue after it has fulfilled its role. Based on the potent protective effect of NTF protein in ischemic brain damage (Fig . 8 ) and the considerable transfer of a foreign gene into ischemic brain (Fig. 9) , an I @ . . expression, and each experiment, including the current data, has other problems to solve such as timing of gene transfer (pretreatment), spatial limitation of the exog enous gene expression around the injection site or peri ventricular ependymal cells, and gene delivery. Devel opment of a more effective and safer vector may be necessary for future practical gene therapy (Ferrari et a!., 1997; Verma and Somia, 1997) . Finally, the route of administration may be another important aspect for the gene therapy of stroke. Direct injection of the vector into brain parenchyma or the ventricle may not be practical for future clinical applications. A development of isch emic tissue-specific targeted gene transfer using intraar terial or venous administration may be expected (Abe et a!., 1997b) . A few additional approaches of gene therapy for stroke could be possible as shown in Fig. 12 (Heistad and Faraci, 1996; Abe et a!., 1997 b) . Stabilization of atherosclerotic plaque and restenosis (Morishita et a!., 1997 (Morishita et a!., , 1998 or stimulation of new collateral vessels may also be fe asible. When these problems are successfully resolved, gene therapy could have great promise for stroke therapy in the future. Neurons may be protected by vector-mediated neurotrophic fac tor (NTF) gene expression. Collateral circulation may be im proved or newly constructed by angiogenic genes such as VEGF or bFGF. Stem cells that are genetically manipulated could be transplanted into the ischemic lesion or NTFs may be directly injected to activate intrinsic stem cells. To avoid the risk of a cerebrovascular accident, arteriosclerotic plaques may be stabi lized, or arterial thrombosis may be inhibited in advance. Modified from Heistad and Faraci, 1996) .
DIFFERENTIA TION OF NEURAL STEM CELLS IN NORMAL DEVELOPMENT
Recent advancements in molecular cell biology have discovered the presence of neural stem cells, even in adult human and monkey brains (Eriksson et aI., 1998; Gould et aI., 1999) . Various neurons and glial cells origi nate from a common stem cell (Fig. 13 ). The stem cell possesses two potentials such as self-renewal and multi directional differentiation. Development and differentia tion of the nervous system depends on the expression of particular genes at particular places and times. This spa tial and temporal pattern of gene expression is regulated by internal molecular programs and external epigenetic environments. Internal influences include transcription factors that act at the DNA level to control gene expres sion, and cell surface and secreted molecules that control the fate of neighboring cells. External factors include secreted factors, nutrients, sensory stimuli, and social experience that mediate patterned changes in the activity of nerve cells. The interaction of these intrinsic and en vironmental factors is critical for the proper diffe rentia-tion of each nerve cell. At each step of differentiation, particular intrinsic determinants (for example, transcrip tion factors) are involved (Fig. 13 ). 'T'he stem cell is positive for nestin at an initial stage, but secondary pro genitor cells become negative for nestin, and turn posi tive for Mash l, Ngn 1/2, and Proxl . This cell then dif ferentiates into a neuronal progenitor cell that is positive for Prox I and Bm4, or into a glial progenitor cell that is positive for repo in the presence of gem (Nakafuku and Nakamura, 1995 ; Nakagawa et aI., 1996; Sakakibara and Okano, 1997 ; Torii et aI., 1997 ; Shimazaki et aI., 1999) . From these neuronal or glial progenitor cells, mature neurons or glial cells are finally produced (Fig. 13) .
The central nervous system originates from the neural crest or neural tube that forms a simple epithelial mono layer. In terms of the spinal cord and peripheral nerves, neural crest cells migrate from the dorsal neural tube along different paths. Many gene factors and NTFs play pivotal roles in the differentiation of neural crest cells into neuron, glia, or muscle cells, and further differen tiation (Figs. 3 and 13) (Takahashi et aI., 1999) . As for the cerebral cortex, the neurons are generated from an epithelial layer of progenitor cells that lines the lateral ventricles. Once they have left the cell cycle, the imma ture neurons migrate out of the ventricular zone to form the cortical plate (future gray matter). Neurons born at early stages within the ventricular zone migrate along with radial glial cells to the deepest layers of the cortical plate. Neurons born at later stages migrate past the ear lier-generated neurons to form the more superficial lay ers of the cortex. Thus, cortical neurons in a deep layer are generated fi rst, and those in an outer layer are gen erated later. Early in normal development, the progenitor cells expand the population of neuronal precursor cells by rapid proliferation, thus giving rise to neurons and additional progenitor cells, finally generating only neu rons (Jesse II and Sanes, 2000) .
ACTIVATION OF NEURAL STEM CELL AFTER CEREBRAL ISCHEMIA
It has been well known that stem cells are present in the bone marrow that generates peripheral blood cells throughout life. However, stem cells in adult mammalian brain are now believed to be present in the hippocampal dentate gyrus (DG) and subventricular zone (SVZ) of the striatum (Gould et aI., 1999 ; Kempermann and Gage, 1999) . Three DG layers such as hilus, subgranular layer, and granular cell layer generate stem cells for the hip pocampus. The SVZ of the striatum provides new neu rons to the olfactory bulb. Although the exact origin of the neuronal progenitor cell is still debated as being either subventricular cells, ependymal cells, or subven tricular astrocytes (Johansson et aI., 1999 ; Doetsch et aI., 1999) , it is interesting that differentiated cells such as ependymal cells or astrocytes could be neuronal pro genitors. These data suggest the possibility of brain cells reverting back to undifferentiated cells and redif ferentiating into neuronal progenitor cells. Thus, these cells have the potential for recovery and rearrange ment of neuronal networks after destruction of the brain by ischemia.
Dividing cells can be detected by the incorporation of BrdU after its administration intraperitoneally. With double staining for the neuronal marker NeuN and cal bindin-D28k, neurogenesis and age-related decreases A were found in the hippocampal DG of adult rats (Kuhn et aI., 1996) . These data explain in part the decreased plas ticity of the aged brain. Based on such a study of normal brain, preliminary studies on a possible activation of neu ral stem cells has been examined in ischemic brains. Proliferation of neuronal precursor cells in the DG was accelerated after 15 minutes of transient forebrain isch emia in mice (Takagi et aI., 1999) . The number of BrdU labeled cells increased in DG and para ventricle regions at 3, 7, and 10 days after reperfusion (Fig. 14) . Liu and Sharp (1999) found a 12-fold increase of BrdU incorpo ration at the subgranular zone of DG between 1 and 2 weeks after 10 minutes of global ischemia in gerbils. A 2-or 4-minute occlusion time was the threshold for isch emia-induced stem cell proliferation in the DG. Confocal microscopy confirmed that 60% of the BrdU positive cells in the granule cell layer expressed neuronal markers NeuN, Calbindin, and MAP-2 at I month after the BrdU labeling, and that many cells expressed glial marker glial fi brillary acidic protein in the dentate hilus between 2 weeks and I month after the BrdU injection (Liu et al., 1998) . Activation of neurogenesis has also been reported in a systemic chemoconvulsant model (Parent et aI., 1997) , where hippocampal network plasticity associated with epileptogenesis may arise from aberrant connec tions formed by newly born dentate granule cells.
These pioneering works suggest that neural stem cells in the DG respond to ischemic injury by increasing the rate of proliferation in the subgranular zone in mice and gerbils. The neuronal and glial progeny derived from the stem cells migrated into different anatomical locations such as the granule cell layer and the dentate hilus. En hanced neurogenesis in the DG may be a compensatory adaptive response to ischemic injury and could promote fu nctional recovery after ischemia. Expression of highly polysialylated neural cell adhesion molecule in mossy fiber of granule cells in adult rat DG could be important in the migration of stem cells Arai, 1993, 1999) .
POTENTIAL OF NEURAL STEM CELL TRANSPLANT A TION FOR THE ISCHEMIC BRAIN
Several trials have been performed to transplant brain cells into ischemic brain. For example, fetal rat hippo campal neurons were stereotaxically transplanted into 5-day-old ischemic hippocampal CA I lesions of adult rat (Aoki et a!., 1993) . In the recipient brain, the trans planted cells survived well and formed clusters in the host CA 1 subfield at 14 or 100 days after the transplan tation and 67% of animals exhibited supragranular mossy fiber sprouting in DG. Hodges et a! . (1997) re ported that fetal CA I grafts promoted recovery from cognitive deficits in marmosets induced by excitotoxic damage to the CA l fi eld.
Novel challenges have begun using various stem cells and modern techniques. The hematopoietic myeloid pro genitor cells (1 x lO s per ILL) cultured from adult mouse bone marrow were implanted into the penumbra of the ischemic striatum at 4 or 24 hours after 3 hours of tran sient MCAO in mice (Li et a!., 1999) . In another experi ment, fresh bone marrow cells (1 x 10 6 per IOILL, in cluding the supportive tissue (stroma) obtained directly from adult rats) were grafted into the penumbra of the ischemic striatum at 4 or 24 hours after 2 hours of tran- A Stem cell activation sient MeAO in rats. The data demonstrated that adult hematopoietic bone marrow cells that were labeled with green fluorescent protein (GFP) survived in the adult mouse and rat brains after ischemia. Migration of SVZ cells was more prominent in the rat model than in the mouse, suggesting that a grafting microenvironment that includes stroma increased the potential for stem cell mi gration. Colocalization of mitotic and apoptotic cells in the graft suggests that ischemic injured brain and the graft cells may revert to an early stage of development to promote repair. In another experiment, neuroepithelial stem cell lines (MHP36), which are genetically engineered to replicate into neurons or glia at 33°C, but cease replication and differentiate at body temperature of 37°C, were trans planted (75,000 cells per 3 ILL) at 2 weeks after 60 min utes of transient MCAO into 8 sites of the striatum and cortex (Veizovic et a!., 1999) . The grafted animals re covered from sensorimotor deficit to a similar level as sham control throughout 18 weeks of testing. With this cell line (MHP36), Sinden et a!. (1997) showed recovery from fu nctional deficit in adult rats after 15 minutes of global ischemia, and found an extensive repopulation of the grafted cells into neuronal and glial phenotypes in the hippocampus. Further study showed that MHP36 stem cell restored cognitive function in marmosets after NMDA-induced excitotoxic hippocampal CA I lesions as effectively as fetal homografts Vir ley et a!., 1999) . 
�.@'differentiation
There could be two ways to use stem cells as a therapy for ischemic brain. One way is to activate intrinsic stem cells located in the hippocampal DG or the SVZ of the caudate (Fig. 15A ). Craig et a\. (1996) showed that in fu sion of EGF into adult mouse ventricles induced mi gration of subependymal cells away from the lateral ven tricle walls into adjacent parenchyma. Kuhn et a\. (1997) found a neurogenesis in olfactory bulb after injection of bFGF or EGF into the ventricle. As mentioned above, these stem cells are also activated after ischemic injury . Addition of NTFs could further potentiate such a spon taneous activation of stem cells after ischemia. A second approach is to transplant manipulated stem cells origi nated from fetal or adult brain, or even embryonic stem cells (Flax et a\., 1998; Vescovi et aI., 1999) into the injured lesion of the brain (Fig. 15B ). However, it is not possible at the current time to make these stem cells divide, differentiate, and migrate to fulfill the space lost by ischemia and to form fu nctionally normal neuron net works. To develop future therapy for human stroke, fur ther experimental studies and a better understanding of the role of each NTF, genetic markers at each stage of stem cell differentiation, and ways of genetic direction to a certain species of brain cells will be essential. Even though it may take time, the prospect of successful re search in the future looks promising.
